Clinical Trial Update: A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial comparing HLX18 to nivolumab (Opdivo) in patients with multiple resected solid tumors, including esophageal/gastric cardia cancer, melanoma, and u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cardia Cancer
• Melanoma
• Urothelial Carcinoma

Drugs mentioned

• HLX18
• OPDIVO (nivolumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Esophageal and/or Cardia Cancer, Melanoma | Phase 1 | Status: NOT_YET_RECRUITING